Suggested remit - To appraise the clinical and cost effectiveness of siponimod within its marketing authorisation for treating secondary progressive multiple sclerosis in adults
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
1304
|
Provisional Schedule
| Committee meeting: 1 |
12 March 2020 |
| Expected publication |
03 June 2020 |
Project Team
| Project lead |
Jeremy Powell |
Email enquiries
| Evidence Review Group / Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
| Companies sponsors |
Novartis (siponimod) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
NHS Great Yarmouth & Waveney CCG |
| |
NHS Islington CCG |
| |
Welsh Government |
| Patient carer groups |
The Brain Charity |
| |
Brain and Spine Foundation - |
| |
Disability Rights UK |
| |
Leonard Cheshire Disability |
| |
MS-UK |
| |
Multiple Sclerosis National Therapy Centres |
| |
Multiple Sclerosis Society |
| |
Multiple Sclerosis Trust |
| |
Muslim Council of Britain |
| |
Neurological Alliance |
| |
Shift.ms |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Sue Ryder |
| Professional groups |
Association of British Neurologists |
| |
British Association of Neuroscience Nurses |
| |
British Geriatrics Society |
| |
British Neuropathological Society |
| |
British Society for Blood and Marrow Transplantation |
| |
British Society of Rehabilitation Medicine |
| |
Chartered Society of Physiotherapy |
| |
Institute of Neurology |
| |
London MS-AHSCT Collaborative Group |
| |
Primary Care Neurology Society |
| |
Therapists in MS |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Occupational Therapists |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Therapists in MS |
| |
UK Clinical Pharmacy Association |
| |
UK Health Forum |
| |
UK Multiple Sclerosis Specialist Nurse Association |
Commentators
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
Novartis (interferon beta 1b) |
| |
Bayer (interferon beta 1b) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Multiple Sclerosis Society Wales |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
Neurological Alliance of Scotland |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Wales Neurological Alliance |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Brain Research Trust |
| |
British Neurological Research Trust |
| |
Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Hospital for Neurology and Neurosurgery |
| |
National Institute for Health Research |
|
Date
|
Update
|
|
16 July 2019
|
Invitation to participate |
|
16 July 2019
|
In progress, Appraisal has been referred to NICE. |
|
20 November 2018 - 18 December 2018
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance